JP2005522476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005522476A5 JP2005522476A5 JP2003582114A JP2003582114A JP2005522476A5 JP 2005522476 A5 JP2005522476 A5 JP 2005522476A5 JP 2003582114 A JP2003582114 A JP 2003582114A JP 2003582114 A JP2003582114 A JP 2003582114A JP 2005522476 A5 JP2005522476 A5 JP 2005522476A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- disorder
- indan
- dibromo
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 19
- 201000010099 disease Diseases 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 208000017520 skin disease Diseases 0.000 claims 12
- 208000019423 liver disease Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 7
- 206010020850 Hyperthyroidism Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 206010020112 Hirsutism Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims 4
- 208000006454 hepatitis Diseases 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000005057 thyrotoxicosis Diseases 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 2
- 208000001348 Chloracne Diseases 0.000 claims 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 208000017701 Endocrine disease Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 208000002260 Keloid Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 108700005075 Regulator Genes Proteins 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 231100000354 acute hepatitis Toxicity 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 210000001117 keloid Anatomy 0.000 claims 2
- 201000011486 lichen planus Diseases 0.000 claims 2
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- -1 pyridin-2-yl-methoxy Chemical group 0.000 claims 2
- 239000005495 thyroid hormone Substances 0.000 claims 2
- 229940036555 thyroid hormone Drugs 0.000 claims 2
- 208000003663 ventricular fibrillation Diseases 0.000 claims 2
- 206010047302 ventricular tachycardia Diseases 0.000 claims 2
- QBMQWMRXNWTLCF-UHFFFAOYSA-N 2-[4,6-dibromo-5-[3-propan-2-yl-4-[(5-thiophen-3-yl-1,2,4-oxadiazol-3-yl)methoxy]phenoxy]-2,3-dihydro-1h-inden-1-yl]acetic acid Chemical compound CC(C)C1=CC(OC=2C(=C3CCC(CC(O)=O)C3=CC=2Br)Br)=CC=C1OCC(N=1)=NOC=1C=1C=CSC=1 QBMQWMRXNWTLCF-UHFFFAOYSA-N 0.000 claims 1
- IBAOSHKSGPSIPT-UHFFFAOYSA-N 2-[4,6-dibromo-5-[4-(naphthalen-2-ylmethoxy)-3-propan-2-ylphenoxy]-2,3-dihydro-1h-inden-1-yl]acetic acid Chemical compound C1=CC=CC2=CC(COC3=CC=C(OC=4C(=C5CCC(CC(O)=O)C5=CC=4Br)Br)C=C3C(C)C)=CC=C21 IBAOSHKSGPSIPT-UHFFFAOYSA-N 0.000 claims 1
- UKVKVVBZGUXQFX-UHFFFAOYSA-N 2-[4,6-dibromo-5-[4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-3-propan-2-ylphenoxy]-2,3-dihydro-1h-inden-1-yl]acetic acid Chemical compound CC(C)C1=CC(OC=2C(=C3CCC(CC(O)=O)C3=CC=2Br)Br)=CC=C1OCC=1C(C)=NOC=1C UKVKVVBZGUXQFX-UHFFFAOYSA-N 0.000 claims 1
- GAJSOXNPNODZNA-UHFFFAOYSA-N 2-[4,6-dibromo-5-[4-[(4-fluorophenyl)methoxy]-3-propan-2-ylphenoxy]-2,3-dihydro-1h-inden-1-yl]acetic acid Chemical compound CC(C)C1=CC(OC=2C(=C3CCC(CC(O)=O)C3=CC=2Br)Br)=CC=C1OCC1=CC=C(F)C=C1 GAJSOXNPNODZNA-UHFFFAOYSA-N 0.000 claims 1
- GKUPMCWFIBTWPA-UHFFFAOYSA-N 2-[4,6-dibromo-5-[4-[(5-methyl-1,2-oxazol-3-yl)methoxy]-3-propan-2-ylphenoxy]-2,3-dihydro-1h-inden-1-yl]acetic acid Chemical compound CC(C)C1=CC(OC=2C(=C3CCC(CC(O)=O)C3=CC=2Br)Br)=CC=C1OCC=1C=C(C)ON=1 GKUPMCWFIBTWPA-UHFFFAOYSA-N 0.000 claims 1
- OCIODFSKYHFPIE-UHFFFAOYSA-N 2-[4,6-dibromo-5-[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]-3-propan-2-ylphenoxy]-2,3-dihydro-1h-inden-1-yl]acetic acid Chemical compound CC(C)C1=CC(OC=2C(=C3CCC(CC(O)=O)C3=CC=2Br)Br)=CC=C1OCC(=C(O1)C)N=C1C1=CC=CC=C1 OCIODFSKYHFPIE-UHFFFAOYSA-N 0.000 claims 1
- SJQCYYMHFWVSJH-UHFFFAOYSA-N 2-[5-[4-[(4-amino-6-anilino-1,3,5-triazin-2-yl)methoxy]-3-propan-2-ylphenoxy]-4,6-dibromo-2,3-dihydro-1h-inden-1-yl]acetic acid Chemical compound CC(C)C1=CC(OC=2C(=C3CCC(CC(O)=O)C3=CC=2Br)Br)=CC=C1OCC(N=1)=NC(N)=NC=1NC1=CC=CC=C1 SJQCYYMHFWVSJH-UHFFFAOYSA-N 0.000 claims 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims 1
- UBMWERFQWJYCPE-UHFFFAOYSA-N 4-[[4-[[4,6-dibromo-1-(carboxymethyl)-2,3-dihydro-1h-inden-5-yl]oxy]-2-propan-2-ylphenoxy]methyl]benzoic acid Chemical compound CC(C)C1=CC(OC=2C(=C3CCC(CC(O)=O)C3=CC=2Br)Br)=CC=C1OCC1=CC=C(C(O)=O)C=C1 UBMWERFQWJYCPE-UHFFFAOYSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- 206010037083 Prurigo Diseases 0.000 claims 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 229930003316 Vitamin D Chemical class 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000005108 alkenylthio group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000005109 alkynylthio group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical group 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 125000004129 indan-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])C2([H])* 0.000 claims 1
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- CGJMROBVSBIBKP-UHFFFAOYSA-N malonamic acid Chemical compound NC(=O)CC(O)=O CGJMROBVSBIBKP-UHFFFAOYSA-N 0.000 claims 1
- 230000003818 metabolic dysfunction Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Chemical class 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0208384.8A GB0208384D0 (en) | 2002-04-11 | 2002-04-11 | Novel compounds |
| PCT/EP2003/001304 WO2003084915A1 (en) | 2002-04-11 | 2003-02-10 | Novel thyroid receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005522476A JP2005522476A (ja) | 2005-07-28 |
| JP2005522476A5 true JP2005522476A5 (https=) | 2006-03-30 |
Family
ID=9934685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003582114A Pending JP2005522476A (ja) | 2002-04-11 | 2003-02-10 | 新規甲状腺受容体リガンド |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20050171104A1 (https=) |
| EP (1) | EP1492756A1 (https=) |
| JP (1) | JP2005522476A (https=) |
| KR (1) | KR20040102080A (https=) |
| CN (1) | CN1324001C (https=) |
| AU (1) | AU2003210234A1 (https=) |
| CA (1) | CA2481976A1 (https=) |
| GB (1) | GB0208384D0 (https=) |
| IL (1) | IL164406A0 (https=) |
| WO (1) | WO2003084915A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8501223B2 (en) | 2003-06-20 | 2013-08-06 | Hill's Pet Nutrition, Inc. | Methods for dietary management of cats to avoid hyperthyroidism |
| CN1882327A (zh) | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
| WO2006088246A1 (ja) * | 2005-02-18 | 2006-08-24 | Takeda Pharmaceutical Company Limited | Ｇｐｒ３４受容体機能調節剤 |
| MX2007014502A (es) | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos para el tratamiento de enfermedades del higado graso. |
| AU2007207991B2 (en) * | 2006-01-26 | 2011-08-04 | Hill's Pet Nutrition, Inc. | Methods and compositions for treating feline hyperthyroidism |
| CN101511205A (zh) * | 2006-07-03 | 2009-08-19 | 希尔氏宠物营养品公司 | 用于在甲状腺机能亢进的猫科动物中预防或治疗心血管疾病的组合物和方法 |
| EP2061767B1 (de) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung |
| WO2008054675A2 (en) * | 2006-10-31 | 2008-05-08 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| RU2527948C2 (ru) | 2009-04-20 | 2014-09-10 | Мицубиси Танабе Фарма Корпорейшн | Новый агонист бета рецептора тиреоидного гормона |
| KR20120060207A (ko) | 2009-08-26 | 2012-06-11 | 사노피 | 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도 |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| CN105237381A (zh) * | 2015-10-14 | 2016-01-13 | 湖南华腾制药有限公司 | 5-羟基-1-茚酮的制备方法 |
| CN105330525A (zh) * | 2015-10-25 | 2016-02-17 | 湖南华腾制药有限公司 | 7-羟基-1-茚酮的制备方法 |
| JP2020500199A (ja) | 2016-11-21 | 2020-01-09 | バイキング・セラピューティクス・インコーポレイテッド | グリコーゲン蓄積症の治療方法 |
| AU2018280118B2 (en) | 2017-06-05 | 2021-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| US12090252B2 (en) | 2017-09-14 | 2024-09-17 | Riken | Method for producing retinal tissues |
| CN107929273A (zh) * | 2017-12-01 | 2018-04-20 | 崔坤元 | 肝脏靶向药物 |
| ES3053674T3 (en) | 2018-03-22 | 2026-01-23 | Viking Therapeutics Inc | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| CA3132804A1 (en) | 2019-03-13 | 2020-09-17 | Sumitomo Dainippon Pharma Co., Ltd. | Method for evaluating quality of transplant neural retina, and transplant neural retina sheet |
| JP7760131B2 (ja) | 2020-09-11 | 2025-10-27 | 株式会社Racthera | 移植用組織のための媒体 |
| WO2022054925A1 (ja) | 2020-09-11 | 2022-03-17 | 国立研究開発法人理化学研究所 | 神経網膜を含む細胞凝集体とマトリクスとを含む複合体及びその製造方法 |
| EP4428227A4 (en) | 2021-11-19 | 2025-11-12 | Riken | PROCESS FOR PRODUCING LEAF-SHAPED RETINAL TISSUE |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9713739D0 (en) * | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
| GB9828442D0 (en) * | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
| GB9927056D0 (en) * | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| ES2242723T3 (es) * | 2000-02-17 | 2005-11-16 | Bristol-Myers Squibb Company | Ligandos derivados de anilina para el receptor de la tiroides . |
| GB0015205D0 (en) * | 2000-06-21 | 2000-08-09 | Karobio Ab | Bioisosteric thyroid receptor ligands and method |
| GB0111861D0 (en) * | 2001-05-15 | 2001-07-04 | Karobio Ab | Novel compounds |
-
2002
- 2002-04-11 GB GBGB0208384.8A patent/GB0208384D0/en not_active Ceased
-
2003
- 2003-02-10 KR KR10-2004-7016192A patent/KR20040102080A/ko not_active Withdrawn
- 2003-02-10 EP EP03745755A patent/EP1492756A1/en not_active Withdrawn
- 2003-02-10 CA CA002481976A patent/CA2481976A1/en not_active Abandoned
- 2003-02-10 AU AU2003210234A patent/AU2003210234A1/en not_active Abandoned
- 2003-02-10 JP JP2003582114A patent/JP2005522476A/ja active Pending
- 2003-02-10 WO PCT/EP2003/001304 patent/WO2003084915A1/en not_active Ceased
- 2003-02-10 US US10/510,645 patent/US20050171104A1/en not_active Abandoned
- 2003-02-10 CN CNB038099373A patent/CN1324001C/zh not_active Expired - Fee Related
-
2004
- 2004-02-10 IL IL16440604A patent/IL164406A0/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005522476A5 (https=) | ||
| DE02735262T1 (de) | Schilddrüsenhormon-rezeptor-antagonisten zur behandlung von herzerkrankungen & metabolischen störungen | |
| JP2004533450A5 (https=) | ||
| JP2013536855A5 (https=) | ||
| JP2007502806A5 (https=) | ||
| JP2004529174A5 (https=) | ||
| PT1614418E (pt) | Utilização de derivados do ácido (-)(3-tri-halometilfenoxi) (4- halofenil) acético para o tratamento de hiperuricemia | |
| RU2005138592A (ru) | Производные пропионовой кислоты, полезные в лечении липидных расстройств | |
| JP2006501295A5 (https=) | ||
| JP2004534825A5 (https=) | ||
| EP2089023A2 (en) | Methods of treating neuropathic pain with agonists of ppar-gamma | |
| JP2005522476A (ja) | 新規甲状腺受容体リガンド | |
| PT1458369E (pt) | Gel compreendendo pelo menos um retinóide e peróxido de benzoílo | |
| CZ282548B6 (cs) | Farmaceutický přípravek | |
| CN101189216B (zh) | Desferrithiocin聚醚类似物 | |
| RU2007116317A (ru) | Гексафторизопропанол-замещенные производные простых эфиров | |
| JP2005521721A5 (https=) | ||
| EP0915823B1 (fr) | Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations | |
| JP2015508068A5 (https=) | ||
| EP2464349A2 (en) | Use of ppar delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases | |
| EP0947496A1 (fr) | Composés bicycliques-aromatiques et leur utilisation en médecine humaine ou vétérinaire ainsi qu'en cosmétologie | |
| JP2005532331A5 (https=) | ||
| RU2005109163A (ru) | НОВЫЕ СОЕДИНЕНИЯ 2-АРИЛТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ PPARα И PPARγ | |
| JP2020504120A5 (https=) | ||
| JP2007515467A5 (https=) |